Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Antigen Express Inc. Stories

2012-05-09 06:26:08

WORCESTER, Mass. and TORONTO, May 9, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a Scientific Advisory Board (SAB) has been established for its wholly-owned oncology immuno-therapeutics subsidiary, Antigen Express, Inc. The function of the SAB is to provide advice and assistance to Antigen Express in respect of the clinical and regulatory programs for the Company's immuno-therapeutic cancer vaccines. The initial focus of the...

2012-05-08 06:31:02

WORCESTER, Mass. and TORONTO, May 8, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that abstracts featuring the AE37 breast cancer vaccine clinical program of Generex wholly-owned subsidiary Antigen Express, Inc. will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) taking place June 1-5, 2012 in Chicago, IL. An abstract entitled "From bench to bedside: The use of the li-Key technology...

2012-04-03 06:25:52

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference. The annual AACR meeting is one of the largest national cancer conferences in the...

2012-03-14 08:30:00

WORCESTER, Mass. and TORONTO, March 14, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that a review of the Antigen Express proprietary platform technology for generation of immunotherapeutic vaccines has been published in the peer-reviewed journal Vaccine. The Company is developing therapeutic vaccines for serious unmet medical needs, such as cancer. The article, entitled "CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class...

2012-02-27 08:30:00

WORCESTER, Mass. and TORONTO, Feb. 27, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) announced today that Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., will give a presentation at the upcoming Cancer Immunotherapy Summit to be held in Boston, MA February 27-29. The presentation, entitled "Recent Advances in Understanding the Immune System and the Role of Th cells," will be given Wednesday, February 29 at 9:45 am EST. The...

2012-02-01 07:00:00

WORCESTER, Mass. and TORONTO, Feb. 1, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines. A number of products developed with this technology are currently in clinical development. The patent helps to secure the novel Antigen Express vaccine technology platform in the...

2012-01-17 08:30:00

WORCESTER, Mass. and TORONTO, Jan. 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a detailed interview conducted at the BioTech Showcase 2012 during last week's JPMorgan Healthcare Conference in San Francisco with Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., regarding the Antigen Express breast cancer vaccine, is available on the Stock News Now website (www.stocknewsnow.com) and on the Generex...

2012-01-04 12:56:00

WORCESTER, Mass. and TORONTO, Jan. 4, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that representatives of the Company's wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in San Francisco from January 8 through 13. (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b ) Representatives of Antigen Express will be available over the course of the conference to meet with prospective...

2012-01-03 08:00:00

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37. Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall...

2011-12-21 08:30:00

WORCESTER, Mass. and TORONTO, Dec. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that the previously announced Bloomberg Television segment on the Antigen Express breast cancer vaccine aired yesterday evening (December 20, 2011). The segment can be viewed on the Company's website at www.generex.com or on the Bloomberg website at http://www.bloomberg.com/video/83137924/. (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)...